News
SERA
10.04
+0.80%
0.08
Weekly Report: what happened at SERA last week (0415-0419)?
Weekly Report · 2d ago
Weekly Report: what happened at SERA last week (0408-0412)?
Weekly Report · 04/15 12:24
Why JPMorgan Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Friday's Mid-Day Session
JPMorgan Chase & Co. Shares dipped 5.1% to $185.49 following first-quarter earnings on Friday. PaxMedica, Inc. Shares jumped 143% after the company reported better-than-expected results on Thursday. Rent the Runway shares jumped 162% on Thursday after reporting mixed results.
Benzinga · 04/12 18:47
Weekly Report: what happened at SERA last week (0401-0405)?
Weekly Report · 04/08 12:30
Weekly Report: what happened at SERA last week (0325-0329)?
Weekly Report · 04/01 12:26
iBio, Mesoblast, Kodiak Sciences among healthcare movers
IBio, Mesoblast, Kodiak Sciences among healthcare movers. S&P 500 Health Care Sector +0.18% to 1725.9. Pharmaceuticals, Biotechnology & Life Science contributes 58% to index. S&p 500 Healthcare Equipment & Services among healthcare mover.
Seeking Alpha · 03/28 14:01
Sera Prognostics (SERA) Upgraded to Buy: Here's What You Should Know
NASDAQ · 03/25 16:00
Aehr Test Systems Reports Preliminary Results, Joins Dyne Therapeutics, United Airlines And Other Big Stocks Moving Lower On Monday
Shares of Aehr Test System tumbled 18.1% to $12.01 on Monday. The company reported preliminary third-quarter and FY24 results below estimates. The Dow Jones index fell around 100 points in today's session. Vimeo, Canopy Growth Corporation and United Airlines also recorded losses.
Benzinga · 03/25 14:32
Weekly Report: what happened at SERA last week (0318-0322)?
Weekly Report · 03/25 12:30
Sera Prognostics' PreTRM: A Speculative Buy In Women's Health
Sera Prognostics specializes in women's health diagnostics with its PreTRM test, offering personalized risk assessment for preterm birth. The company's flagship product analyzes specific proteins and gestational age to provide an 88% sensitivity for predicting preterm births. SERA's potential in the prenatal care market is vast and justifies it as a speculative "buy"
Seeking Alpha · 03/24 06:15
Sera Prognostics’ PreTRM Test Faces Regulatory Risks: The Financial Implications of Potential FDA Hurdles
TipRanks · 03/22 06:02
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 03/21 03:50
Analysts Are Bullish on These Healthcare Stocks: Tenaya Therapeutics (TNYA), Telix Pharmaceuticals Ltd. (TLPPF)
TipRanks · 03/21 03:40
Analysts Offer Insights on Healthcare Companies: Sera Prognostics (SERA) and Tenaya Therapeutics (TNYA)
TipRanks · 03/21 02:50
Analysts Are Bullish on Top Healthcare Stocks: Tenaya Therapeutics (TNYA), Sera Prognostics (SERA)
TipRanks · 03/21 02:30
SERA Stock Earnings: Sera Prognostics Beats EPS, Misses Revenue for Q4 2023
Sera Prognostics reported earnings per share of -25 cents. The company reported revenue of $41,000. This was 18% worse than the analyst estimate for the company to report revenue of  $50,000  Sera reported earnings were above the analyst estimates.
Investorplace · 03/21 00:54
Sera Prognostics, Inc. (SERA) Reports Q4 Loss, Lags Revenue Estimates
NASDAQ · 03/20 21:20
Sera Prognostics Unveils New Investor Presentation Update
TipRanks · 03/20 20:23
Sera Prognostics GAAP EPS of -$0.25 in-line, revenue of $0.04M misses by $0.01M
Sera Prognostics reports Q4 GAAP EPS of -$0.25 in-line, revenue of $0.04M misses by $ 0.01M. The company is expected to report its quarterly results on March 20, 2024. Sera has a market capitalization of $1.2 billion.
Seeking Alpha · 03/20 20:16
Sera Prognostics: Q4 Earnings Insights
Sera Prognostics reported its Q4 earnings on March 20. The company beat estimates by 4.0% and revenue was down $24 thousand from the same period last year. Sera ProGNostics is expected to announce its earnings Wednesday, March 20 at 4.05pm.
Benzinga · 03/20 20:10
More
Webull provides a variety of real-time SERA stock news. You can receive the latest news about Sera Prognostics, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About SERA
Sera Prognostics, Inc. is a women's health diagnostic company utilizing its proprietary proteomics and bioinformatics platform, and significant data resources to enhance maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. It has built a proteomics and bioinformatics platform to characterize the biology of pregnancy and to discover and validate key protein biomarkers found in blood that are accurate predictors of dynamic changes that occur during pregnancy. Its commercial product, the PreTRM test, is a validated, commercially available blood-based biomarker test to predict the risk of a premature delivery, also known as preterm birth. The PreTRM test is a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation that provides a prediction of the expectant mother’s risk of delivering spontaneously before 37 weeks’ gestation.